Of the 20 trial participants, only two patients to-date have received an initial dosing, which took place in December 2022 (refer ASX release 7 December 2022).
All of the data prepared in this release are from a total of two patients. I have not attained a PhD in biostatistics (please chip in if you have), but a barely-commenced clinical study where n=2 is a curious basis for a 5 page press release from a public company.
The 'Disclosure Committee' want to show off how well their trial is going, for obvious reasons. Not convinced disclosures like this will restore investor confidence or sp.
CPH Price at posting:
1.7¢ Sentiment: None Disclosure: Not Held